Viking Therapeutics (NASDAQ:VKTX) Trading Up 3.2%

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) shares were up 3.2% during mid-day trading on Friday . The stock traded as high as $11.42 and last traded at $11.29. Approximately 1,096,467 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 1,773,753 shares. The stock had previously closed at $10.94.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on VKTX shares. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Viking Therapeutics in a research note on Thursday, February 9th. Stifel Nicolaus started coverage on Viking Therapeutics in a research report on Thursday. They set a “buy” rating and a $22.00 target price on the stock. Raymond James upped their target price on Viking Therapeutics from $11.00 to $12.00 and gave the stock an “outperform” rating in a research report on Thursday, February 9th. Maxim Group upped their target price on Viking Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, December 19th. Finally, StockNews.com started coverage on Viking Therapeutics in a research report on Thursday. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.50.

Viking Therapeutics Price Performance

The company has a fifty day moving average of $10.08 and a 200-day moving average of $6.34. The firm has a market cap of $927.70 million, a P/E ratio of -13.00 and a beta of 0.77.

Viking Therapeutics (NASDAQ:VKTX – Get Rating) last announced its quarterly earnings results on Wednesday, February 8th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, sell-side analysts expect that Viking Therapeutics, Inc. will post -0.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Laurion Capital Management LP bought a new position in Viking Therapeutics in the 2nd quarter valued at $3,826,000. Cornerstone Capital Inc. grew its stake in Viking Therapeutics by 3.5% in the 3rd quarter. Cornerstone Capital Inc. now owns 143,980 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 4,840 shares during the period. PVG Asset Management Corp bought a new position in shares of Viking Therapeutics during the 3rd quarter worth $40,000. Virtu Financial LLC bought a new position in shares of Viking Therapeutics during the 3rd quarter worth $46,000. Finally, Jump Financial LLC bought a new position in shares of Viking Therapeutics during the 3rd quarter worth $163,000. Institutional investors own 34.71% of the company’s stock.

Viking Therapeutics Company Profile

(Get Rating)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.